BEONE MEDICINES

6160
249.4000.16% ( -0.400 )
Delay Closed: Nov 16, 16:08:11

Overview

BEONE MEDICINES (6160)

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and i...

Open
249.800
High
252.400
Low
248.000
Prev. Close
249.800
Volume
2.95M
Turnover
737.44M
Avg Price
249.560
Bid/Ask Ratio
-87.02%
Amplitude
1.76%
52wk High
267.000
Volume Ratio
0.54
Turnover Ratio
0.21%
52wk Low
153.000
HK Mkt Cap
355.95B
Market CapHKD
384.65B
P/ETTM
53.55
P/EDynamic
43.30
P/EStatic
--
EPSTTM
4.66
EPSDynamic
5.76
EPSStatic
--
BVPS
26.31
P/B
9.48
HK Shares
1.43B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.54B
Min lot size
100
Currency
HKD

BEONE MEDICINES Analyst Rating

View more

Forecast & Rating

Nov 13, 2026
Price forecast
HK$283.5413.69%
Forecast & RatingStrong buy
16analysts
  • Strong buy75.00%
  • Buy18.75%
  • Hold6.25%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    BeiGene closed essentially flat at HKD249.4, down marginally 0.16% from the prior close of HKD249.8, reflecting profit-taking pressure following its recent push to a 52-week high of HKD267. Intraday action showed early strength touching HKD252 in the morning session, before weakening to the daily low of HKD248 in afternoon trading. Fundamentals remain robust—Q3 net profit surged 210.72% year-over-year to HKD3.02 billion on revenues of HKD14.83 billion (up 34.93% YoY). Major brokers have aggressively raised price targets, with Daiwa, CLSA, Citi, and UBS all updating their outlooks recently; UBS's latest target stands at USD529. Year-to-date gains of 35.18% leave the stock just 6.59% below its 52-week peak, trading near all-time highs. The stock trades on elevated metrics—PE ratio of 53.55 and PB ratio of 9.48—warranting some caution on valuations.

  2. Nov, 13

    BeOne Medicines slipped 2.3% today to close at HKD249.8, as profit-taking mounted following the stock's recent strong rally. The morning session recovered to HKD251.6, only to retreat in the afternoon and settle at HKD249.8. The pullback comes despite impressive Q3 earnings: net profit surged 210.7% year-over-year to HKD30.19 billion, operating revenue rose 34.9% to HKD14.83 billion, and EPS jumped 215% to HKD1.96, prompting multiple broker target price upgrades — CLSA raised to HKD336.8, Citi to USD507, and UBS to USD529. On the clinical front, lead candidate Brukinsa secured FDA priority review designation. Technically, the stock remains above both 20-day and 60-day moving averages, with year-to-date gains of 35.4% and just 6.4% distance to the 52-week high of HKD267. However, the valuation remains elevated at P/E of 53.6x, warranting caution given high market expectations.

  3. Nov, 12

    BeOne Medicines rose 1.6% to HK$255.8 today, primarily supported by robust Q3 2026 earnings results that showed net profit surging 210.7% year-over-year to HK$3.02 billion, prompting the company to raise full-year guidance as 9M26 cumulative net profit reached $849 million, up 285% year-over-year. Following the earnings release, multiple analysts raised target prices in succession: UBS to $529, Citi to $507, Daiwa to $476, and CLSA to HK$336.8, while the company's product Brukinsa simultaneously received FDA priority review designation. The afternoon trading session showed pressure, with prices declining to HK$253 levels, reflecting profit-taking following yesterday's 52-week high of HK$267. The stock trades just 4.2% below its recent peak, has gained 38.6% year-to-date, and carries a forward PE of 54.9, indicating elevated valuation levels.

  4. Nov, 11

    BeiGene pulled back 0.16% today, as profit-taking followed yesterday's fresh 52-week high of HKD 267; the stock fell over 1% in the morning session before rebounding to close at HKD 251.8. Solid fundamentals drove recent gains, with Q3 net profit surging 210.72% year-over-year and EPS reaching HKD 1.9616; multiple brokers lifted price targets in response, including Daiwa to USD 476, Citi to USD 507, and UBS to USD 529. Year-to-date gains of 36.48% have positioned the stock within 5.69% of its 52-week peak. However, the stock trades at a lofty PE of 54x, leaving sustainability dependent on whether earnings growth can sustain current valuations.

  5. Nov, 10

    BeiGene pulled back to HKD252.2 today, declining 5.54% from the 52-week peak set yesterday, as profit-taking pressured the stock following a sharp rally, though fundamentals remain robust. Q3 results significantly outperformed expectations with net profit surging 210.72% year-over-year to HKD3.02 billion, operating revenue rising 34.93% to HKD14.83 billion, and earnings per share reaching HKD1.9616, up 215.1% year-on-year—marking record quarterly profitability; the company raised full-year guidance accordingly. Multiple international brokerages responded positively, with UBS, Citi, and Daiwa raising price targets to USD529, USD507, and USD476 respectively, while CLSA lifted its target to HKD336.8. In parallel, the company's key oncology asset Brukinsa secured FDA priority review designation, supporting future commercialization. Year-to-date gains exceed 36.69%, with the stock trading meaningfully above both the 20-day and 60-day moving averages; however, the elevated valuation multiple (PE of 54.15x) likely contributed to today's correction.

News

Bullish vs. Bearish — Last 3 Months

12.4k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    morning_wind

    If you think silicon-based is too risky and want to look at carbon-based, you should still be cautious about bottom-fishing in Chinese internet stocks in Hong Kong. Pharmaceutical leaders are relatively at low points and have the potential to emerge first.$XIAOMI-W(01810.HK)$BEONE MEDICINES(06160.HK)$INNOVENT BIO(01801.HK)

  • D
    Dolphin Research

    BEKE rolls out HK buyback shield; Xiaomi faces earnings test tonight | Daily News Recap

    0526 | Dolphin Research Focus: 🐬 Macro/Industry. 1) The US and Iran reached a framework for an MoU; Iran would reopen the Strait of Hormuz within 30 days of signing, the US would unfreeze $12bn of Iranian assets, and both sides would implement a ceasefire.

    This would significantly ease near-term Middle East tensions and stabilize the global energy supply chain (about 30% of crude flows through the strait). It supports a pullback in oil and a rebound in energy stocks.

    However, the arrangement is temporary and does not address core issues such as Iran's nuclear program. Longer-term execution remains uncertain.

    2) Hang Seng Indexes Company announced the results of its regular quarterly index rebalancing. ...

    图片 1,共 1 张
    Today’s Key News Recap
  • M
    momoM

    $Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticals

    mp.weixin.qq.com/s/gihUP-...

    当前环境异常,完成验证后即可继续访问。

    当前环境异常,完成验证后即可继续访问。

    mp.weixin.qq.com